Text Size

The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Antoun Nader, Northwestern University
ClinicalTrials.gov Identifier:
NCT01272921
First received: January 7, 2011
Last updated: February 15, 2013
Last verified: February 2013
History of Changes
  Purpose

The duration of motor block for infragluteal parabiceps sciatic nerve block following TKR may vary between 12-36 hrs depending on the amount of local anesthetic given.


Condition Intervention
The Duration of Motor Block for Sciatic Block Following TKR May Vary Between 12-36 Hrs Depending on the Amount of Local Anesthetic Given.
 Drug: Bupivacaine
Drug: Ropivacaine

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Dose Response Study for Duration of Analgesia Using Bupivacaine and Ropivacaine for Infragluteal Parabiceps Sciatic Block

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • The Duration of Motor Block for Sciatic Block Following TKR [ Time Frame: 3 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Differences between local anesthetics [ Time Frame: 3 Days ] [ Designated as safety issue: No ]

Enrollment: 142
Study Start Date: November 2010
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
GROUP 1
Varying does to determine duration of analgesia following a sciatic nerve block
 Drug: Bupivacaine
Varying doses to determine the duration of analgesia
GROUP 2
Varying does to determine duration of analgesia following a sciatic nerve block
 Drug: Ropivacaine
Varying doses to determine the duration of analgesia

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Adult patients (>18 years of age) who are undergoing elective total knee arthroplasty will be included in the study.

Criteria

Inclusion Criteria:

  • Adult patients (>18 years of age) who are undergoing elective total knee arthroplasty will be included in the study.

Exclusion Criteria:

  • Exclusion criteria for the study are patient refusal to be included in the study, contraindications to regional anesthesia, history of allergy to amide local anesthetics, the presence of a progressive neurological deficit, the presence of coagulopathy or infection, or pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01272921

Locations
United States, Illinois
Northwestern University, Feingberg School of Medicine
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
  More Information

No publications provided

Responsible Party: Antoun Nader, Associate Professor of Anesthesiology, Northwestern University
ClinicalTrials.gov Identifier: NCT01272921     History of Changes
Other Study ID Numbers: STU00035380
Study First Received: January 7, 2011
Last Updated: February 15, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Bupivacaine
Ropivacaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
 Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 21, 2013